Additional studies that test CSF1R inhibitors in combination with standard of care or immune therapy are currently ongoing [e.g., BLZ945 with PRD001 anti-programed cell death-1 (PD1) in solid tumors including recurrent GBM (NCT02829723) and PLX3397 with temozolomide and radiotherapy in newly diagnosed GBM (NCT01790503)]. This evidence concerns the gene CSF1R and glioblastoma.